^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IDH1R132H peptide vaccine

    i
    Other names: IDH1R132H peptide vaccine, IDH1 peptide vaccine
    Associations

    News

    Trials
    Company:
    German Cancer Research Center
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    6ms
    AMPLIFY-NEOVAC: AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma (clinicaltrials.gov)
    P1, N=60, Active, not recruiting, German Cancer Research Center | Recruiting --> Active, not recruiting | Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition • Tumor mutational burden • IO biomarker
    |
    ATRX (ATRX Chromatin Remodeler)
    |
    Bavencio (avelumab) • IDH1R132H peptide vaccine
    almost2years
    AMPLIFY-NEOVAC: AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma (clinicaltrials.gov)
    P1, N=60, Recruiting, German Cancer Research Center | Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2022 --> Sep 2023
    Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition • Tumor mutational burden • IO biomarker
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • ATRX (ATRX Chromatin Remodeler)
    |
    IDH1 R132
    |
    Bavencio (avelumab) • IDH1R132H peptide vaccine